All In Biotech

Drug Trial Radar · NCT06435429

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment

Last checked: Nov 19, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 550 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

550

Planned (sponsor's estimate)

Start

Aug 13, 2024

Primary completion

Apr 28, 2028

Study completion Oct 18, 2030

Sponsor

Lead sponsor
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
Sponsor type
Industry
First posted
May 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous T-DXd treatment.

Conditions

  • Metastatic HER2-positive Breast Cancer

Interventions

  • ZanidatamabDrug

    Administered by intravenous infusion

  • TrastuzumabDrug

    Administered by intravenous infusion

  • EribulinDrug

    Administered by intravenous infusion

  • VinorelbineDrug

    Administered by intravenous infusion

  • GemcitabineDrug

    Administered by intravenous infusion

  • CapecitabineDrug

    Given orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) Per RECIST Version 1.1 As Assessed by Blinded Independent Central Review (BICR)Time frame: Until disease progression or death, up to approximately 44 months

Locations

166 sites in 15 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Scottsdale - PPDS

    Phoenix, Arizona · Recruiting

  • Arizona Oncology Tucson - Wilmot

    Tucson, Arizona · Withdrawn

  • University of Arizona Cancer Center

    Tucson, Arizona · Recruiting

  • The Oncology Institute Of Hope And Innovation

    Cerritos, California · Recruiting

  • Los Angeles Hematology Oncology Medical Group Glendale

    Glendale, California · Recruiting

  • USC-Norris Comprehensive Cancer Center - Investigational Drug Service IDS

    Los Angeles, California · Recruiting

  • UCSF at Mission Bay MB

    San Francisco, California · Recruiting

  • University of Colorado-Cancer Center-PPDS

    Aurora, Colorado · Recruiting

  • Rocky Mountain Cancer Centers

    Denver, Colorado · Recruiting

  • Medstar Georgetown University Hospital

    Washington D.C., District of Columbia · Recruiting

  • Washington Cancer Center

    Washington D.C., District of Columbia · Recruiting

  • Florida Cancer Specialists Research South

    Fort Myers, Florida · Recruiting

  • Mayo Clinic Jacksonville - PPDS

    Jacksonville, Florida · Recruiting

  • Florida Cancer Specialists Research North

    St. Petersburg, Florida · Recruiting

  • Florida Cancer Specialists Research East

    West Palm Beach, Florida · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Minnesota Oncology Hematology

    Coon Rapids, Minnesota · Recruiting

  • Mayo Clinic - PPDS

    Rochester, Minnesota · Recruiting

  • Saint Luke's Cancer Institute

    Kansas City, Missouri · Recruiting

  • Hackensack Meridian Health

    Hackensack, New Jersey · Recruiting

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey · Recruiting

  • Memorial Sloan Kettering

    Long Island City, New York · Recruiting

  • Perlmutter Cancer Center 160 E 34th St

    New York, New York · Recruiting

  • The Mount Sinai Hospital

    New York, New York · Recruiting

  • Columbia University Medical Center 161 Fort Washington

    New York, New York · Recruiting

  • Messino Cancer Center

    Asheville, North Carolina · Recruiting

  • Duke Cancer Institute

    Durham, North Carolina · Recruiting

  • UNC Central Investigational Drug Services

    Morrisville, North Carolina · Recruiting

  • Oncology Hematology Care (OHC)

    Cincinnati, Ohio · Recruiting

  • University Hospitals Cleveland Medical Center 11100 Euclid Ave

    Cleveland, Ohio · Withdrawn

  • Abramson Cancer Center of The University of Pennsylvania

    Philadelphia, Pennsylvania · Recruiting

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • Rhode Island Hospital

    Providence, Rhode Island · Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Recruiting

  • Texas Oncology - Fort Worth

    Fort Worth, Texas · Recruiting

  • U.T. MD Anderson Cancer Center, Investigational Pharmacy Services

    Houston, Texas · Recruiting

  • Millennium Research and Clinical Development

    Houston, Texas · Withdrawn

  • Maryland Oncology Hematology Healing Way - USOR

    Irving, Texas · Recruiting

  • Medical Oncology Hematology Consultants

    Irving, Texas · Recruiting

  • Nexus Health

    Irving, Texas · Recruiting

Showing 40 of 166 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.